FLT3 and acute lymphoblastic leukemia: A trial conducted in KMT2A rearranged infant ALL investigating incorporation of lestaurtinib, an FLT3 inhibitor, with intensive chemotherapy, based on the FLT3 overexpression, revealed that addition of lestaurtinib did not improve outcome [32,33].